share_log

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K: Current report

Transcode Therapeutics | 8-K:重大事件
美股SEC公告 ·  2024/08/28 18:09

Moomoo AI 已提取核心訊息

Transcode Therapeutics received two deficiency notices from Nasdaq regarding potential delisting. The first notice on August 13 cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 to August 12. The company is ineligible for the standard 180-day compliance period due to two reverse stock splits exceeding a 250:1 ratio in the past two years.The second notice on August 15 addressed non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported equity of $1.32 million as of June 30. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma equity to $3.7 million, there is no guarantee Nasdaq will consider this adjustment.The company has appealed both delisting determinations, with the delisting action temporarily stayed pending a Nasdaq Hearings Panel review scheduled for October 1, 2024. There is no assurance that additional extension will be granted or that compliance will be regained for continued Nasdaq Capital Market listing.
Transcode Therapeutics received two deficiency notices from Nasdaq regarding potential delisting. The first notice on August 13 cited failure to maintain the minimum $1.00 bid price requirement for 30 consecutive business days from July 1 to August 12. The company is ineligible for the standard 180-day compliance period due to two reverse stock splits exceeding a 250:1 ratio in the past two years.The second notice on August 15 addressed non-compliance with the minimum stockholders' equity requirement of $2.5 million, as the company reported equity of $1.32 million as of June 30. While a July 2024 equity offering added approximately $2.4 million in net proceeds, bringing pro forma equity to $3.7 million, there is no guarantee Nasdaq will consider this adjustment.The company has appealed both delisting determinations, with the delisting action temporarily stayed pending a Nasdaq Hearings Panel review scheduled for October 1, 2024. There is no assurance that additional extension will be granted or that compliance will be regained for continued Nasdaq Capital Market listing.
Transcode Therapeutics 收到來自納斯達克的兩份退市通知。第一份通知於8月13日發出,指出從7月1日到8月12日,連續30個交易日未能維持最低1.00美元的買盤價格要求。由於過去兩年內進行過兩次超過250:1比例的拆股並股,該公司不符合標準的180天合規期。第二份通知於8月15日發出,關於不符合最低股東權益要求250萬美元的通知,因爲截至6月30日,該公司報告的股東權益爲132萬美元。儘管2024年7月的股權發行增加了大約240萬美元的淨收益,使得形式上的股東權益達到370萬美元,但並沒有保證納斯達克會考慮這一調整。該公司已對這兩項退市決定提出上訴,退市行動在等待定於2024年10月1日的納斯達克聽證小組審查期間暫時中止。並不能保證會獲得額外的延期,或者能恢復合規以繼續納斯達克資本市場的上市。
Transcode Therapeutics 收到來自納斯達克的兩份退市通知。第一份通知於8月13日發出,指出從7月1日到8月12日,連續30個交易日未能維持最低1.00美元的買盤價格要求。由於過去兩年內進行過兩次超過250:1比例的拆股並股,該公司不符合標準的180天合規期。第二份通知於8月15日發出,關於不符合最低股東權益要求250萬美元的通知,因爲截至6月30日,該公司報告的股東權益爲132萬美元。儘管2024年7月的股權發行增加了大約240萬美元的淨收益,使得形式上的股東權益達到370萬美元,但並沒有保證納斯達克會考慮這一調整。該公司已對這兩項退市決定提出上訴,退市行動在等待定於2024年10月1日的納斯達克聽證小組審查期間暫時中止。並不能保證會獲得額外的延期,或者能恢復合規以繼續納斯達克資本市場的上市。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息